Holen Sie sich die Stockscreener-App
1.12
2.75%
0.03
Schlusskurs vom Vortag:
$1.09
Offen:
$1.07
24-Stunden-Volumen:
7.89M
Relative Volume:
2.63
Marktkapitalisierung:
$124.14M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.6788
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
-21.13%
1M Leistung:
-13.85%
6M Leistung:
-68.09%
1J Leistung:
-84.31%
1-Tages-Spanne:
$1.00
$1.14
1-Wochen-Bereich:
$1.00
$1.43
52-Wochen-Spanne:
$1.00
$8.83
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.12 | 124.14M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.03 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.36 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.20 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
247.43 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.67 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.
Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World
iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World
Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Q1 Earnings Estimate for FATE Issued By Leerink Partnrs - MarketBeat
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know - Yahoo Finance
Fate Therapeutics (FATE) Projected to Post Quarterly Earnings on Monday - MarketBeat
FY2024 Earnings Forecast for FATE Issued By Leerink Partnrs - Defense World
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Fate Therapeutics, Inc. (FATE) Investors to Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys - accessnewswire.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of “Hold” from Analysts - Defense World
What is Leerink Partnrs’ Estimate for FATE Q1 Earnings? - Defense World
Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
SG Americas Securities LLC Acquires 10,511 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Navigating FATE Stock: Fate Therapeutics Inc Journey - The InvestChronicle
Analysts review Fate Therapeutics Inc’s rating - Knox Daily
CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail
Take off with Fate Therapeutics Inc (FATE): Get ready for trading - SETE News
Fate Therapeutics Inc (FATE) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap (FATE) - Seeking Alpha
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics Inc [FATE] Investment Appeal on the Rise - Knox Daily
We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate - Yahoo Finance
Fate Therapeutics Inc (FATE)’s stock performance: a year in review - US Post News
FATE 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys Before Mar. 22nd Deadline in Securities Class Action - ACCESS Newswire
Fate Therapeutics Inc (FATE)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Fate Therapeutics' SWOT analysis: stock poised for catalysts amid clinical progress - MSN
Fate Therapeutics Inc (NASDAQ: FATE) Is A Buzzing Hot Stock - Stocks Register
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Assenagon Asset Management S.A. - Defense World
Equities Analysts Offer Predictions for FATE FY2025 Earnings - Defense World
Research Analysts Set Expectations for FATE FY2025 Earnings - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Update - MarketBeat
JPMorgan Chase & Co. Has $6.43 Million Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Bought by JPMorgan Chase & Co. - MarketBeat
Day 0 of Loss Streak for Fate Therapeutics Stock with 0% Return (vs. -20% YTD) [1/22/2025] - Trefis
Fate Therapeutics' SWOT analysis: stock poised for growth amid clinical progress - Investing.com
Fate Therapeutics’ chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Nigeria
Fate Therapeutics CEO sells shares worth $13,405 By Investing.com - Investing.com Canada
Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock By Investing.com - Investing.com South Africa
Fate Therapeutics executive sells $9,269 in common stock By Investing.com - Investing.com Canada
Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Canada
Insider Selling: Fate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $13,405.70 in Stock - MarketBeat
Barclays PLC Has $1.49 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. Announces Retirement of J. Scott Wolchko as Treasurer, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Fate Therapeutics appoints new CEO, enters advisory pact By Investing.com - Investing.com Canada
Fate Therapeutics appoints new CEO, enters advisory pact - Investing.com
Fate Therapeutics Announces Executive Leadership Transition - TipRanks
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fate Therapeutics Inc-Aktie (FATE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TAHL CINDY | See Remarks |
Jan 10 '25 |
Sale |
1.55 |
5,654 |
8,764 |
336,707 |
| Valamehr Bahram | President and CEO |
Jan 10 '25 |
Sale |
1.54 |
8,705 |
13,406 |
349,364 |
2.61%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):